|Day Low - High||0.48 - 0.50|
|Year Low - High||0.32 - 2.60|
More Healthcare/Biotech NewsOctober 16, 2017
HIIQ’s $50 million Stock BuyBack Program, Record Preliminary Unaudited Q3 Results, & Update on Florida TPA Application ProcessOctober 13, 2017
Catalyst Health Network & UnitedHealthcare’s Accountable Care Organization Making Positive Impact on Patients’ HealthOctober 9, 2017
Are You Caught In The Healthcare Coverage Gap?September 29, 2017
Health Insurance Innovations, Inc. (HIIQ) Reaffirms Financial Outlook for Full Year 2017
Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years for breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.
Atossa is the only company in the WORLD attempting to conquer breast cancer the way they are and have stated “The best way to treat a disease is to prevent it in the first place.” They are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density. Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer. However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal with their topical endoxifen program is to treat high breast density with a local, topical drug.
Atossa is also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.
Their proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Their patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.
“Charging Ahead” Vista Partners Weekly Market Update 10-21-17
MARKET OVERVIEW, RESULTS & WEEK AHEAD The US markets charged ahead once again this week, hitting a new record high in all five trading sessions. The Dow eclipsed a new milestone of 23,000 for the first time and ending the week at 23,328.63 up 2% on the
The Importance Of October’s Breast Cancer Awareness Month & Beyond
Hіѕtоrу of Brеаѕt Cаnсеr Awаrеnеѕѕ Mоnth Breast cancer awаrеnеѕѕ mоnth wаѕ created іn 1985 аѕ a соllаbоrаtіvе еffоrt bеtwееn thе American Academy of Fаmіlу Phуѕісіаnѕ аnd AѕtrаZеnеса Healthcare Fоundаtіоn аnd CаnсеrCаrе, Inс., аnd vаrіоuѕ ѕроnѕоrѕ. Tоdау, іt hаѕ grоwn tо include a раrtnеrѕhір оf nаtіоnаl
Atossa’s Microcatheter Technology Is Being Enlisted By Leading Researchers In Upcoming Breast Cancer Study
The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about